BioCentury
ARTICLE | Company News

AcelRx submits Zalviso NDA

October 1, 2013 12:47 AM UTC

AcelRx Pharmaceuticals Inc. (NASDAQ:ACRX) submitted an NDA to FDA for Zalviso sufentanil sublingual microtablet system to manage moderate to severe acute pain in a hospital setting. The company submit...